DCT

2:26-cv-06905

Incyte Corp v. Sun Pharma Canada Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:

  • Case Identification: 2:26-cv-06905, D.N.J., 07/16/2026

  • Venue Allegations: Venue is alleged to be proper as Defendants conduct business throughout the United States, including New Jersey, and as foreign corporations, they may be sued in any judicial district.

  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Opzelura® (ruxolitinib) cream constitutes an act of patent infringement under the Hatch-Waxman Act.

  • Technical Context: The technology concerns topical pharmaceutical formulations of ruxolitinib, a Janus kinase (JAK) inhibitor, used for treating inflammatory skin disorders such as atopic dermatitis and vitiligo.

  • Key Procedural History: The lawsuit was initiated in response to Defendants' Paragraph IV certifications asserting that the patents-in-suit are invalid or would not be infringed by their proposed generic product. This action is part of a series of litigations between the parties concerning the same ANDA, with prior suits involving different patents listed in the FDA's Orange Book for Opzelura®. The complaint notes that the original ANDA filer, Taro Pharmaceuticals Inc., was amalgamated into Defendant Sun Pharma Canada Inc.

Case Timeline

Date Event
2010-05-21 U.S. Patent 12,564,593 Priority Date
2019-09-05 U.S. Patent 12,589,096 Priority Date
2025-01-27 Taro sends First Paragraph IV Notice Letter to Incyte
2025-03-13 Incyte files first Hatch-Waxman suit against Taro
2025-04-01 Taro and Sun Canada amalgamate
2025-04-22 Taro sends Second Paragraph IV Notice Letter to Incyte
2025-06-04 Incyte files second Hatch-Waxman suit against Taro
2026-03-03 U.S. Patent 12,564,593 Issues
2026-03-31 U.S. Patent 12,589,096 Issues
2026-04-29 Sun Canada sends Third Paragraph IV Notice Letter to Incyte (re: '593 Patent)
2026-06-23 Sun Canada sends Fourth Paragraph IV Notice Letter to Incyte (re: '096 Patent)
2026-07-16 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,564,593, "Topical Formulation for a JAK Inhibitor," Issued March 3, 2026

The Invention Explained

  • Problem Addressed: The patent background describes the role of Janus kinase (JAK) signaling in inflammatory diseases, including skin disorders like psoriasis ʼ593 Patent, col. 1:21-46 It identifies a need for "stable, easily applied formulations for JAK inhibitors with good skin permeation characteristics" for topical treatment ʼ593 Patent, col. 2:47-52
  • The Patented Solution: The patent discloses a specific oil-in-water emulsion formulation for topically delivering the JAK inhibitor ruxolitinib ʼ593 Patent, abstract This formulation is described as having superior properties, including appearance, stability, and skin permeation, compared to other formulations like water-in-oil emulsions or anhydrous ointments ʼ593 Patent, col. 4:42-55 Figure 1 provides a detailed flowchart for the manufacturing process of the claimed emulsion ʼ593 Patent, Fig. 1
  • Technical Importance: Developing a stable and effective topical formulation for a JAK inhibitor enables localized treatment of skin immune disorders, which could mitigate the systemic side effects associated with oral administration of such compounds.

Key Claims at a Glance

The complaint alleges infringement of one or more claims of the ʼ593 patent without specifying which ones Compl. ¶39 Independent claim 1 is representative of the formulation claims.

  • Independent Claim 1: A pharmaceutical formulation for topical skin application, comprising:
    • An oil-in-water emulsion;
    • from 35% to 65% by weight of water;
    • from 10% to 40% by weight of a mixture of petrolatum, C16-18 fatty alcohols, mineral oil, a triglyceride, and a silicone oil;
    • from 2% to 6% by weight of a mixture of a glyceryl fatty ester and a sorbitan fatty ester;
    • from 0.05% to 5% by weight of a polysaccharide;
    • from 10% to 35% by weight of a mixture of an alkylene glycol and a polyalkylene glycol; and
    • from 0.5%-1.5% of the ruxolitinib phosphoric acid salt by weight on a free base basis.

U.S. Patent No. 12,589,096, "Ruxolitinib formulation for reduction of itch in atopic dermatitis," Issued March 31, 2026

The Invention Explained

  • Problem Addressed: The patent background identifies pruritus (itch) as a "cardinal feature" of atopic dermatitis (AD) that impairs quality of life, and notes that existing therapies do not exert a "direct effect on itch alleviation" ʼ096 Patent, col. 1:45-63
  • The Patented Solution: The invention provides methods for reducing itch and treating AD by administering a topical ruxolitinib cream (0.75% or 1.5%) two times per day ʼ096 Patent, abstract The patent describes clinical trial results where this method leads to a significant reduction in the patient's itch Numerical Rating Scale (NRS) score from baseline ʼ096 Patent, col. 2:7-21
  • Technical Importance: The claimed method provides a targeted approach to rapidly alleviate itch, a primary and burdensome symptom of atopic dermatitis, addressing a previously unmet need in the management of the disease.

Key Claims at a Glance

The complaint alleges infringement of one or more claims without specifying them Compl. ¶48 Independent claim 1 is representative of the method of treatment claims.

  • Independent Claim 1: A method of treating moderate atopic dermatitis in a human patient, comprising:
    • administering to the skin a topical formulation comprising from 0.5%-1.5% ruxolitinib, two times per day;
    • continuing administration for at least 8 weeks;
    • wherein the patient has a Body Surface Area (BSA) of AD involvement from 3% to 20% at baseline;
    • wherein the patient has an itch NRS score of ≥4 at baseline;
    • wherein the patient achieves Investigator's Global Assessment (IGA) treatment success with a score of 0 or 1 and ≥2 grade improvement from baseline at week 8; and
    • wherein the patient achieves at least a 4 point reduction in itch NRS score from baseline at week 8.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is the "Proposed Generic Opzelura® Product," which is the subject of Sun's ANDA No. 219040 Compl. ¶17

Functionality and Market Context

  • The complaint alleges this is a generic version of Incyte's Opzelura® (ruxolitinib) cream, intended for the same uses, which include the treatment of atopic dermatitis and nonsegmental vitiligo Compl. ¶1 Compl. ¶¶11-12 The filing of the ANDA itself, seeking FDA approval to market this product before the expiration of the patents-in-suit, constitutes the alleged act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶39 Compl. ¶48 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide specific technical details of the accused product's formulation or proposed label beyond alleging that it is a generic version of Opzelura®. The analysis is therefore based on the premise that the ANDA product will possess the characteristics of the branded drug.

'593 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical formulation for topical skin application, wherein the formulation is an oil-in-water emulsion... The complaint alleges on information and belief that the Proposed Generic Opzelura® Product is an oil-in-water cream formulation containing ruxolitinib for topical application. ¶39 col. 7:1-4
from 35% to 65% by weight of the formulation of water The complaint does not provide sufficient detail for analysis of this element. ¶39 col. 7:5-6
from 10% to 40% by weight of the formulation of a mixture of petrolatum, C16-18 fatty alcohols, mineral oil, a triglyceride, and a silicone oil The complaint does not provide sufficient detail for analysis of this element. ¶39 col. 7:7-11
from 2% to 6% by weight of the formulation of a mixture of a glyceryl fatty ester and a sorbitan fatty ester The complaint does not provide sufficient detail for analysis of this element. ¶39 col. 7:12-14
from 0.5%-1.5% of (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl] propanenitrile phosphoric acid salt by weight of the formulation on a free base basis. The complaint alleges that the Proposed Generic Product contains ruxolitinib, and on information and belief, will fall within the claimed concentration range. ¶1; ¶39 col. 7:22-29
  • Identified Points of Contention:
    • Scope Questions: A central question will be whether the precise formulation detailed in Sun's confidential ANDA falls within the specific percentage ranges for each category of excipients (e.g., water, oil mixture, emulsifier mixture) as recited in the claims.
    • Technical Questions: The infringement analysis will depend on the chemical and physical properties of the excipients used in Sun's proposed product and whether they meet the functional and structural definitions of the components recited in the claims, such as "polysaccharide" or "alkylene glycol".

'096 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating moderate atopic dermatitis in a human patient in need thereof comprising: administering to the human patient's skin a topical formulation...two times per day... The complaint alleges that Sun's ANDA seeks approval for a generic product whose proposed label will instruct and encourage physicians and patients to administer the product for the treatment of atopic dermatitis. ¶11; ¶13; ¶51 col. 29:2-6
continuing the administration of the topical formulation for at least 8 weeks... On information and belief, the proposed label for the generic product will instruct or suggest a duration of treatment that meets this limitation. ¶11; ¶13; ¶51 col. 29:7-8
wherein the patient achieves IGA treatment success...at week 8 of the administration... The proposed product is alleged to be a bioequivalent generic, and its label will thus contain efficacy data demonstrating that administration according to the label results in this clinical outcome. ¶1; ¶51 col. 29:14-18
wherein the human patient achieves at least a 4 point reduction in itch Numerical rating Scale score from baseline at week 8 of the administration. The proposed product is alleged to be a bioequivalent generic, and its label will thus contain efficacy data demonstrating that administration according to the label results in this clinical outcome. ¶1; ¶51 col. 29:19-22
  • Identified Points of Contention:
    • Scope Questions: A principal dispute may involve the "picket fence" limitations, which define the method by its clinical outcomes (e.g., "achieves IGA treatment success...at week 8"). This raises the legal question of whether such statements of a result, rather than an action taken by a user, can serve as enforceable limitations of a method claim.
    • Technical Questions: An evidentiary question may arise as to whether Sun's proposed label will contain instructions and efficacy data that directly correspond to each of the specific patient population and outcome parameters required by the asserted claims, thereby inducing infringement by healthcare providers.

V. Key Claim Terms for Construction

  • The Term: "oil-in-water emulsion" (from '593 Patent)

    • Context and Importance: This term defines the fundamental nature of the claimed formulation. The infringement analysis for the '593 patent hinges on whether Sun's ANDA product is properly classified as an "oil-in-water emulsion" as that term is understood in the context of the patent.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification does not provide an explicit definition, which may support giving the term its plain and ordinary meaning as understood by a person of ordinary skill in the pharmaceutical arts.
      • Evidence for a Narrower Interpretation: The patent provides a detailed manufacturing process ʼ593 Patent, Fig. 1 and specific exemplary formulations ʼ593 Patent, Tables 2-5 A party could argue these examples implicitly define the claimed "oil-in-water emulsion" as one made by a specific process or having a composition closely tied to the disclosed embodiments.

  • The Term: "achieves at least a 4 point reduction in itch Numerical rating Scale score from baseline at week 8" (from '096 Patent)

    • Context and Importance: Practitioners may focus on this term because it is a "result-oriented" or "picket fence" limitation. Its construction is critical because it raises the legal question of whether a method claim can be validly limited by a clinical outcome, which is not an action performed by the direct infringer (e.g., a doctor or patient).
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: A party may argue this language simply describes the inherent result of practicing the method steps (administering the drug for 8 weeks) and helps define the specific, patented method that produces this beneficial outcome, distinguishing it from prior art methods.
      • Evidence for a Narrower Interpretation: A party may argue that this is not a valid method step but rather a statement of intended result or patient response, which cannot serve as a basis for infringement because the user of the method does not "perform" the step of "achieving" a specific clinical score.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for both patents-in-suit Compl. ¶¶42-43 Compl. ¶¶51-52 The inducement allegation is based on the assertion that Sun's proposed product label will instruct and encourage physicians and patients to perform the infringing methods Compl. ¶51 Contributory infringement is alleged on the basis that the proposed generic product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶52
  • Willful Infringement: The complaint does not use the word "willful" but alleges that Sun had knowledge of the patents via Paragraph IV notice letters sent "No earlier than April 29, 2026" for the '593 patent and "No earlier than June 23, 2026" for the '096 patent Compl. ¶35 Compl. ¶37 The complaint also states that the case is "exceptional" and seeks attorneys' fees under 35 U.S.C. § 285, which is often associated with findings of willfulness or other litigation misconduct Compl. ¶46 Compl. ¶55

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of compositional scope: Does the specific formulation disclosed in Sun's confidential ANDA fall within the quantitative ranges for each component recited in the composition claims of the '593 patent, or will there be a material difference in one or more excipients or their concentrations?
  • A second central issue will be one of claim enforceability: Can the method claims of the '096 patent, which are defined by specific clinical trial outcomes (e.g., achieving a certain IGA or itch reduction score at week 8), be validly enforced against an ANDA filer, or will these "picket fence" limitations be found to be improper statements of intended result rather than actionable method steps?
  • A key evidentiary question will be one of inducement: Assuming the method claims of the '096 patent are valid, will the language in Sun's proposed product label be found to specifically instruct or encourage medical professionals to prescribe the drug in a manner that directly performs all the steps of the claimed method, including adhering to the specified patient population criteria?
Loading Amended Complaint